Company Filing History:
3 out of 3,222 
2 out of 21 Years Active: 2020-2023
Title: Innovations by Brendan Parr in Cancer Treatment
Introduction
Brendan Parr is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors that target specific enzymes involved in cancer treatment. With a total of three patents to his name, Parr's work is paving the way for advancements in immunotherapy.
Latest Patents
Parr's latest patents focus on TDO2 and IDO1 inhibitors. These inhibitors are designed to modulate the activity of tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1. They are particularly useful for treating immunosuppression and medical conditions that benefit from the inhibition of tryptophan degradation. Additionally, these inhibitors enhance the effectiveness of anti-cancer treatments by administering anti-cancer agents and addressing tumor-specific immunosuppression associated with cancer.
Career Highlights
Throughout his career, Brendan Parr has worked with notable companies such as Genentech, Inc. and Newlink Genetics Corporation. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and the development of effective cancer treatments.
Collaborations
Parr has collaborated with esteemed colleagues, including Richard Pastor and Zhonghua Pei. These partnerships have further enriched his research and development efforts in the field of cancer therapeutics.
Conclusion
Brendan Parr's innovative work in developing TDO2 and IDO1 inhibitors represents a significant advancement in cancer treatment. His contributions are vital in the ongoing fight against cancer and immunosuppression.